All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NaV1.7
Therapeutic Area: Neurology Product Name: NaV1.7
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2021
Details:
Navega Therapeutics is the first to apply a variant of CRISPR (and ZFs) that acts as an epigenetic modulator to treat pain. It concludes that long-lasting analgesia via targeted in vivo epigenetic repression of NaV1.7 methodology might help in management of persistent pain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AKE-1018
Therapeutic Area: Neurology Product Name: AKE-1018
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Weill Cornell Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
